Importance Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma
(CM) is rising despite a lack of endorsement as standard of care. Objective To develop …

Background/purpose Melanomas account for only approximately 4% of diagnosed skin
cancers in the United States but are responsible for the majority of deaths caused by skin …

Background Multiple studies have reported on the accuracy of the prognostic 31-gene
expression profile test for cutaneous melanoma. Consistency of the test results across …

Importance The performance of prognostic gene expression profile (GEP) tests for
cutaneous melanoma is poorly characterized. Objective To systematically assess the …

PURPOSE Current guidelines for postoperative management of patients with stage I-IIA
cutaneous melanoma (CM) do not recommend routine cross-sectional imaging, yet many of …

Background Many patients with low-stage cutaneous melanoma will experience tumor
recurrence, metastasis, or death, and many higher staged patients will not. Objective To …

Despite significant progress in the development of treatment options, melanoma remains a
leading cause of death due to skin cancer. Advances in our understanding of the genetic …

Background Prognostic assessment of cutaneous melanoma relies on historical,
clinicopathological, and phenotypic risk factors according to American Joint Committee on …

Melanoma, which is an aggressive skin cancer, is currently the fifth and seventh most
common cancer in men and women, respectively. The American Cancer Society reported …

Given recent developments in the treatment of metastatic melanoma, early detection of
disease recurrence is crucial. The aim of this single-centre retrospective cohort study was to …